Noronha, V., Patil, V., Joshi, A., Chougule, A., Bhattacharjee, A., Kumar, R., . . . Prabhash, K. (2017). Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy. Ecancermedicalscience.
Chicago-tyylinen lähdeviittausNoronha, Vanita, et al. "Impact of Exon 19 Versus Exon 21 EGFR-activating Mutation On Outcomes With Upfront Pemetrexed–carboplatin Chemotherapy." Ecancermedicalscience 2017.
MLA-viiteNoronha, Vanita, et al. "Impact of Exon 19 Versus Exon 21 EGFR-activating Mutation On Outcomes With Upfront Pemetrexed–carboplatin Chemotherapy." Ecancermedicalscience 2017.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.